Search

everythinglearnresearchcommunity

for

Search:↓

NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

ERK activation spreads between cells in mouse skin, linked to cell division and influenced by TPA and EGF receptors.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

LRIG1 is linked to better survival in Merkel cell carcinoma.

Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.

Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.

Axitinib treatment turned a man's grey hair back to black.

QLT0267 stops hair follicle cell growth and movement.

Overexpressing PKCepsilon in mice reduces papillomas but increases carcinomas.

Recombinant human epidermal growth factor is versatile, effective, and safe for long-term skin and mucosal treatments.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

CXCR2 in skin cells promotes tumor growth.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

c-Kit is important for heart regeneration and cancer development.

ERG increases SOX9, promoting prostate cancer growth and invasion.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.

Entospletinib effectively prevents eye and skin GVHD in mice.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

KIT's role in skin cells is not entirely independent, as other cells can influence its function.

Transglutaminase-3 is often reduced in esophageal cancer.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Antizyme reduces tumor growth and normalizes skin cell development affected by MEK.